Current Research Studies
A PHASE 1/2, MULTI-CENTER, DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF QUIZARTINIB ADMINISTERED IN COMBINATION WITH RE-INDUCTION CHEMOTHERAPY, AND AS A SINGLE-AGENT CONTINUATION THERAPY, IN PEDIATRIC RELAPSED/REFRACTORY AML SUBJECTS AGED 1 MONTH TO < 18 YEARS (AND YOUNG ADULTS AGED UP TO 21 YEARS) WITH FLT3-ITD MUTATIONS
ADVL1822_Quiz
What is the goal of the study?
Quizartinib is a Class III receptor tyrosine kinase (RTK) inhibitor exhibiting highly potent and selective inhibition of feline McDonough sarcoma-like tyrosine kinase 3 (FLT3). Quizartinib is currently being studied as a treatment for acute myeloid leukemia (AML).
Who can participate in the study?
Please contact the study team listed below to learn more.